ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

ASCO 2026 featured encouraging clinical data across several cancer vaccines and oncology therapies, including Moderna/MSD’s intismeran, which reduced recurrence and death risk by 49% in melanoma and lifted 5-year cancer-free survival to 68.8% versus 49.1% for pembrolizumab alone. Dana-Farber’s NeoVax extended median overall survival by 11.6 months in glioblastoma, while J&J’s subcutaneous Rybrevant Faspro posted a 42% ORR in head and neck cancer with more than one-third of responders achieving complete responses. Offset by policy concerns around RFK Jr.’s push to deprioritize mRNA vaccine research and cut $500m in BARDA funding, the article is constructive for oncology biotech but highlights regulatory risk.

Analysis

The near-term winners are less the vaccine platforms themselves than the companies that can pair them with an established immunotherapy backbone and a regulated manufacturing/distribution footprint. That matters because personalized oncology vaccines are operationally intensive: if efficacy holds, the bottleneck shifts from science to patient identification, sequencing turnaround, and bespoke batch release, which favors incumbents with global oncology sales forces and pharma-grade supply chains. In that sense, the signal is not just mRNA optionality for MRNA, but a broader validation of combination-immunotherapy franchises that can absorb vaccine add-ons without needing a full commercial buildout.

The glioblastoma read-through is more important than the headline survival number. The apparent sensitivity to treatment sequencing implies the market may be underestimating how much value lies in trial design and biomarker selection rather than the platform alone; that reduces confidence in broad claims, but increases the odds that a smaller, better-selected subset can produce registrational data. If that pattern persists, expect more capital to migrate from diffuse vaccine shots-on-goal toward precision oncology programs that can prove mechanism in small, high-need populations.

The policy backdrop is a real overhang for MRNA: politicization risk does not kill the oncology thesis, but it can extend funding timelines, raise regulatory uncertainty, and compress the multiple until the company shows that its cancer program can advance with limited federal support. Conversely, JNJ’s subcutaneous delivery angle is commercially meaningful because it lowers site-of-care friction and can accelerate uptake if approved, especially in a setting where physicians want faster, more manageable administration after prior lines of therapy. The contrarian view is that the market may be overpricing the incremental benefit of vaccine science and underpricing the platform winner that already has commercial muscle and an approvable label expansion path.

Key Decisions for Investors

• Long JNJ vs. long-only biotech basket: use JNJ as the cleaner monetization of oncology innovation and potential label expansion; target 6-12 months with lower scientific binary risk than vaccine-only names.
• Tactical underweight/short MRNA into strength over the next 1-3 months: the stock can rerate on oncology data, but policy risk and funding uncertainty can cap the multiple until a clear partnership or non-federal financing path emerges.
• Pair trade: long JNJ / short XBI for 3-6 months — hedge broad biotech beta while expressing preference for commercially validated oncology execution over platform-duration risk.
• If MRNA sells off on policy headlines, buy downside-hedged calls 6-12 months out: asymmetric payoff if the cancer program becomes the proof point that de-risks the platform beyond vaccine politics.
• Watch for follow-on data in glioblastoma and melanoma sequencing; if later-stage trials preserve the benefit, add to oncology-exposed names on any pullback because the market will likely reprice these as combination-immunotherapy franchises rather than pure vaccine stories.